Early functional outcomes following partial gland cryo-ablation

Area of Science:

• Urology
• Oncology
• Medical Devices

Background:

• Partial gland cryo-ablation (PGCA) is an emerging treatment for prostate cancer.
• Limited data exists on the functional outcomes, specifically urinary and sexual health, following PGCA.
• Understanding these outcomes is crucial for patient counseling and treatment selection.

Purpose of the Study:

• To evaluate functional outcomes after PGCA, focusing on lower urinary tract symptoms (LUTS) and erectile function (EF).
• To stratify outcomes based on the baseline severity of LUTS and EF.
• To identify clinical factors associated with significant changes in LUTS and EF post-treatment.

Main Methods:

• Prospective outcomes registry of 100 men undergoing primary PGCA.
• Assessment of International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) pre-treatment and at 6 months.
• Univariate and multivariate analyses to identify factors associated with clinically significant changes.

Main Results:

• Overall cohort showed a non-significant decrease in mean IPSS (-2.1 units, p > 0.05).
• Significant IPSS improvements observed in men with moderate (-4.2 units, p=0.001) and severe (-11.1 units, p=0.001) baseline LUTS.
• Mean SHIM score decreased significantly overall (-5.1 units, p=0.001), with notable declines in men with no ED (-7.6 units, p=0.001) and mild/mild-to-moderate ED (-6.5 units, p=0.001).
• No clinical factors were significantly associated with changes in IPSS or SHIM scores.

Conclusions:

• Stratifying outcomes by baseline LUTS and EF severity is essential for understanding PGCA's impact.
• PGCA may offer functional benefits for urinary symptoms in men with moderate to severe LUTS.
• Sexual function may be negatively impacted, particularly in men with pre-existing erectile dysfunction.